Form 4: Quest Diagnostics SVP Mark Delaney Reports Stock Transactions

Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports the acquisition and disposition of company stock related to a performance stock award.

Summary

• Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership.
• On March 4, 2025, Delaney acquired 5,317 shares of common stock at $173.74 per share as settlement of a performance stock award.
• On the same day, Delaney disposed of 1,823 shares at $173.74 per share to cover tax withholding obligations.
• Following these transactions, Delaney beneficially owns 9,477 shares of Quest Diagnostics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine stock transactions related to executive compensation. There is no indication of positive or negative implications for the company's performance.

Positives

• The acquisition of shares through a performance stock award suggests Delaney's performance met certain company goals.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to executive compensation and tax obligations.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates